Mizuho Asset Management Co. Ltd. increased its position in Celgene Corp. (NASDAQ:CELG) by 45.6% during the second quarter, Holdings Channel reports. The fund owned 21,495 shares of the biopharmaceutical company’s stock after buying an additional 6,731 shares during the period. Mizuho Asset Management Co. Ltd.’s holdings in Celgene Corp. were worth $2,120,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Capital Asset Advisory Services LLC bought a new position in Celgene Corp. during the first quarter worth $303,000. Webster Bank N. A. boosted its position in shares of Celgene Corp. by 41.0% in the first quarter. Webster Bank N. A. now owns 4,438 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 1,290 shares in the last quarter. Bath Savings Trust Co boosted its position in shares of Celgene Corp. by 2.9% in the first quarter. Bath Savings Trust Co now owns 82,446 shares of the biopharmaceutical company’s stock valued at $8,252,000 after buying an additional 2,329 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of Celgene Corp. by 8.0% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 3,101 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 229 shares in the last quarter. Finally, Skylands Capital LLC boosted its position in shares of Celgene Corp. by 7.4% in the first quarter. Skylands Capital LLC now owns 28,400 shares of the biopharmaceutical company’s stock valued at $2,843,000 after buying an additional 1,950 shares in the last quarter. 77.75% of the stock is owned by hedge funds and other institutional investors.

Celgene Corp. (NASDAQ:CELG) traded down 0.31% during trading on Thursday, hitting $109.24. 301,903 shares of the stock were exchanged. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $128.39. The firm has a market cap of $84.67 billion, a PE ratio of 46.17 and a beta of 1.31. The stock’s 50-day moving average price is $110.08 and its 200-day moving average price is $105.06.

Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.05. The firm earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. Celgene Corp.’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 EPS. On average, equities analysts expect that Celgene Corp. will post $5.71 EPS for the current year.

Several equities analysts have commented on CELG shares. BTIG Research reissued a “buy” rating and issued a $138.00 price target on shares of Celgene Corp. in a research report on Sunday, August 21st. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corp. in a research report on Wednesday, June 8th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $136.00 price target on shares of Celgene Corp. in a research report on Friday, August 19th. RBC Capital Markets reissued a “buy” rating on shares of Celgene Corp. in a research report on Tuesday, July 26th. Finally, Bank of America Corp. reissued a “buy” rating and issued a $128.00 price target on shares of Celgene Corp. in a research report on Friday, September 16th. Four analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $138.10.

In other news, Director Gilla Kaplan sold 9,710 shares of the firm’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the completion of the transaction, the director now owns 72,142 shares in the company, valued at approximately $7,678,794.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James J. Loughlin sold 27,500 shares of the firm’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $114.10, for a total transaction of $3,137,750.00. Following the transaction, the director now owns 42,919 shares of the company’s stock, valued at approximately $4,897,057.90. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.